NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40 th Annual J.P. Morgan Virtual Healthcare Conference.

National program establishes early care management, technology innovation and large health system engagement as a strategic priority for supporting the 34 million U.S. individuals living with diabetes ARLINGTON, Va. and SALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The American Diabetes

NEW YORK and SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care,

NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call

Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease NEW YORK and SALT LAKE CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans

Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- St. Joseph's Health and Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to implement an

LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based

LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open.

Jed Fulk Appointed Vice President Sales, Government Accounts NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration

Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 NEW YORK and SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™